Good T cells for bad B cells

Blood

Volumn 119, Issue 12, 2012, Pages 2700-2702

  Cooper, Laurence J N ^a   Jena, Bipulendu ^a   Bollard, Catherine M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DNA MODIFICATION; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84858804212     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-398719     Document Type: Note

References (12)

1. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transducedT cells. Blood. 2012;119(12):2709-2720.
2. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad SciU S A. 1993;90(2):720-724. (Pubitemid 23028937)
3. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modifiedT cells in chronic lymphoid leukemia. NEngl J Med. 2011;365(8):725-733.
4. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologousT cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
5. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targetedT cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18): 4817-4828.
6. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modifiedT cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826.
7. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirectedT cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245-1256.
8. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044.
9. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
10. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specificT cells. Blood. 2008;112(6):2261-2271.
11. Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologousT cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4): 666-668.
12. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration ofT cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.